Evaluation of elabela, visfatin, and chemerin levels as inflammation biomarkers in COVID-19

Basit Öğe Kaydı
dc.authorid0000-0003-4577-4475en_US
dc.contributor.authorMermutluoğlu, Çiğdem
dc.contributor.authorTekin, Recep
dc.date.accessioned2024-03-20T11:03:28Z
dc.date.available2024-03-20T11:03:28Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalıen_US
dc.description.abstractOBJECTIVE: The aim of this study was to investigate if inflammation biomarkers elabela, visfatin, and chemerin will be useful in the diagnosis of patients with COVID-19. PATIENTS AND METHODS: This prospective case-control study included 33 patients with COVID-19 and 30 healthy matched controls. 33 patients, aged 18 years and older, diagnosed with COVID-19 and followed up for one month were included in the study. Blood samples were taken from the patients on the first day they were diagnosed with COVID-19, and levels of elabela (ELA), visfatin, chemerin, white blood cells (WBC), C-reactive protein (CRP) and procalcitonin (PCT) were assessed. Blood samples were also taken from 30 healthy volunteers for the control group. The ELA, visfatin and chemerin levels measured in the patients on day one were compared with those measured in the control group and with the WBC, CRP and PCT levels measured in the patients. RESULTS: Visfatin levels measured in COVID-19 patients were significantly higher than in the healthy control group. There was no significant difference in ELA and chemerin levels between the two groups. A significant positive correlation was found between chemerin and visfatin levels in the patients. A significant negative correlation was found between the levels of ELA-chemerin and ELA-visfatin in the patients. There was no significant correlation between elabela, visfatin and chemerin levels and WBC, CRP, PCT levels. CONCLUSIONS: Measurement of visfatin levels may be helpful in patients with COVID-19. However, two other biomarkers in our study, ELA and chemerin, were found not to be useful in diagnosing COVID-19. New inflammatory biomarkers may help to diagnose a disease in which the inflammatory response is at the forefront, such as COVID-19. New studies are needed on this subject.en_US
dc.identifier.citationMermutluoğlu, Ç. ve Tekin, R. (2023). Evaluation of elabela, visfatin, and chemerin levels as inflammation biomarkers in COVID-19. European Review for Medical and Pharmacological Sciences, 27(22), 11180-11184.en_US
dc.identifier.doi10.26355/eurrev_202311_34487
dc.identifier.endpage11184en_US
dc.identifier.issn2284-0729
dc.identifier.issue22en_US
dc.identifier.pmid38039049
dc.identifier.scopus2-s2.0-85178501807
dc.identifier.scopusqualityQ2
dc.identifier.startpage11180en_US
dc.identifier.urihttps://www.europeanreview.org/wp/wp-content/uploads/11180-11184.pdf
dc.identifier.urihttps://hdl.handle.net/11468/13656
dc.identifier.volume27en_US
dc.identifier.wosWOS:001117615400011
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorMermutluoğlu, Çiğdem
dc.institutionauthorTekin, Recep
dc.language.isoenen_US
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCOVID-19en_US
dc.subjectElabelaen_US
dc.subjectVisfatinen_US
dc.subjectChemerinen_US
dc.titleEvaluation of elabela, visfatin, and chemerin levels as inflammation biomarkers in COVID-19en_US
dc.titleEvaluation of elabela, visfatin, and chemerin levels as inflammation biomarkers in COVID-19
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Evaluation of elabela, visfatin, and chemerin levels as inflammation biomarkers in COVID-19.pdf
Boyut:
318.64 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu